The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.80
Bid: 52.60
Ask: 53.00
Change: -2.30 (-4.17%)
Spread: 0.40 (0.76%)
Open: 55.00
High: 55.00
Low: 52.80
Prev. Close: 55.10
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Factsheet: November 2023

27 Dec 2023 11:15

RNS Number : 9384X
Geiger Counter Ltd
27 December 2023
 

 

 

Geiger Counter Limited Plc 

 

Monthly Investor Report - November 

 

The full monthly factsheet is now available on the Company's website and a summary can be found below. 

 

Document Title (ncim.co.uk)

 

Enquiries: 

? 

For the Investment Manager 

CQS (UK) LLP 

Craig Cleland 

0207 201 5368 

For the Company Secretary and Administrator 

BNP Paribas S.A., Jersey Branch 

Dean Plowman/Ann-Marie Pereira 

01534 813 967/ 01534 709198 

 

----------------------------------------------------------------------- 

 

 

Fund Description 

 

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

 

Portfolio Managers 

 

Keith Watson and Robert Crayfourd 

 

 

Key Advantages for the Investor 

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

 

 

 

 

 

 

Key Fund Facts1 

 

 

Total Gross Assets 

£98.9m 

Reference Currency 

GBP 

Ordinary Shares: 

Net Asset Value 

66.27p 

Mid-Market Price  

53.50p 

Net gearing4 

13.79% 

Discount 

(19.27%) 

 

 

Ordinary Share and NAV Performance2 

 

 

One Month 

Three Months 

One Year 

Three Years 

Five Years 

 

(%) 

(%) 

(%) 

(%) 

(%) 

NAV 

2.21 

26.61 

30.17 

300.42 

215.12 

Share Price 

10.88 

22.99 

11.92

205.71 

132.61 

 

 

Commentary3 

Underpinned by continued utility buying activity, U3O8 ended the month at $80.75/lb, up 8.3% and maintaining recent positive momentum. Latest data from industry consultant UxC showed that utility contracting had reached 200Mlbs in the year to mid-November, the first time in a decade that purchasing had exceeded annual requirements of approximately 170Mlbs. Within this, longer-term contracting also reached a decade high of over 150Mlbs - indicative of the necessity to secure future needs given heightened supply-side risks. Such concerns are highlighted by Niger's coup, the ongoing political tensions between Russia and established Western nuclear markets, as well as the temporary production issues experienced at Cameco operations.

 

Despite the pound gaining nearly 4% against the dollar, the Fund NAV rose over 2% in

November, marginally ahead of sterling returns registered by the Solactive Uranium Pure Play Index.

 

Policy support remained very much in the news with the proposals of 22 countries attending the COP28 climate conference to triple installed nuclear capacity by 2050.

 

Prior to the 1st December gathering, the Swedish nuclear utility Vattenfall submitted detailed plans to enable the construction of additional new reactors at the existing Ringhals facility, while the government launched a review of nuclear power permitting procedures. This was aimed at easing the process for new builds beyond the current arbitrary limitation of 10 in-country reactors. Beyond the delivery of these two new reactors by 2035, the construction of a further ten new large-scale reactors is being considered for commissioning by 2045.

 

The way is being paved for the construction of new generating capacity in the US. The state of Illinois, having already passed legislation allowing construction of Small Modular Reactors (SMRs) of up to 300MW from 2026, is expected to lift the moratorium on new large-scale reactor builds. Meanwhile, in Japan, authorities approved a 20-year life extension for the two operational reactors at Sendai.

 

Elsewhere, Honeywell indicated that its US-based Metropolis conversion facility would reach its expanded output target by the year-end and that its UF6 output was sold out until 2029. While some modest incremental expansion is possible, more meaningful expansion to double current run-rate capacity to licensed operational levels would require government support.

 

Nexgen remained a significant performance contributor with the share price rising over 4% in

sterling terms over the month following the receipt of its provincial environmental permits (the first company in more than 20 years to receive full provincial approval for a uranium project in Saskatchewan, Canada). Having all its First Nations benefits agreements in place, the group has submitted relevant information for the final Federal permit. Neighbouring Fission Energy also made a positive contribution registering a 6% sterling rise in share price. A 9% sterling return registered by Denison, following a positive update on its Wheeler Rivers assets, also helped performance. The main detractor was Ur-Energy which declined nearly 5% in sterling terms giving back some of the strong prior month's 14% sterling gain.

 

 

Gross Leverage

(%)

Commitment Leverage

(%)

Geiger Counter Ltd 

114

11

 

 

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

 

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

 

CQS (Hong Kong) Limited

3305 AIA Tower, 183 Electric Road, North Point, Hong Kong, China

T: +852 3920 8600 | F: +852 2521 3189

 

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

 

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCTRBMTMTITBAJ
Date   Source Headline
13th May 20241:45 pmRNSNet Asset Value(s)
10th May 20244:05 pmRNSNet Asset Value(s)
10th May 20248:00 amRNSNet Asset Value(s)
9th May 202411:15 amRNSExercise of outstanding Subscription Share Rights
8th May 20245:15 pmRNSNet Asset Value(s)
8th May 20244:45 pmRNSCorrection to Diluted Net Asset Value
7th May 20245:30 pmRNSNet Asset Value(s)
7th May 20241:30 pmRNSNotification in regard to Subscription Rights
7th May 20241:15 pmRNSResult of subscription rights exercise
3rd May 20242:20 pmRNSNet Asset Value(s)
2nd May 20242:45 pmRNSNet Asset Value(s)
1st May 20243:35 pmRNSNet Asset Value(s)
30th Apr 20243:30 pmRNSNet Asset Value(s)
30th Apr 20242:00 pmRNSShare Buyback
29th Apr 202412:45 pmRNSNet Asset Value(s)
29th Apr 202412:30 pmRNSShare Buyback
26th Apr 20242:15 pmRNSGCL MONTHLY FACT SHEET MARCH 2024
26th Apr 202412:15 pmRNSNet Asset Value(s)
26th Apr 202412:00 pmRNSShare Buyback
25th Apr 20242:45 pmRNSNet Asset Value(s)
25th Apr 20242:00 pmRNSShare Buyback
24th Apr 20242:40 pmRNSNet Asset Value(s)
24th Apr 20241:30 pmRNSShare Buyback
23rd Apr 20243:30 pmRNSNet Asset Value(s)
23rd Apr 20241:45 pmRNSShare Buyback
22nd Apr 20243:35 pmRNSNet Asset Value(s)
22nd Apr 20241:30 pmRNSShare Buyback
19th Apr 20242:35 pmRNSNet Asset Value(s)
18th Apr 20241:35 pmRNSNet Asset Value(s)
17th Apr 202412:20 pmRNSNet Asset Value(s)
16th Apr 20245:20 pmRNSNet Asset Value(s)
15th Apr 202412:50 pmRNSNet Asset Value(s)
12th Apr 20241:35 pmRNSNet Asset Value(s)
11th Apr 20241:15 pmRNSNet Asset Value(s)
10th Apr 20243:40 pmRNSNet Asset Value(s)
9th Apr 20241:25 pmRNSNet Asset Value(s)
8th Apr 20241:10 pmRNSNet Asset Value(s)
5th Apr 20242:05 pmRNSNet Asset Value(s)
4th Apr 20241:10 pmRNSNet Asset Value(s)
3rd Apr 20242:40 pmRNSNet Asset Value(s)
3rd Apr 20249:00 amRNSInvestment Manager Acquisition
2nd Apr 20243:50 pmRNSNet Asset Value(s)
28th Mar 20241:50 pmRNSNet Asset Value(s)
27th Mar 20241:00 pmRNSNet Asset Value(s)
27th Mar 20249:33 amRNSNotification to Shareholders - Subscription Rights
26th Mar 20242:55 pmRNSNet Asset Value(s)
25th Mar 20241:00 pmRNSNet Asset Value(s)
22nd Mar 20244:45 pmRNSPotential listing on the London Stock Exchange
22nd Mar 20241:15 pmRNSNet Asset Value(s)
21st Mar 20241:25 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.